Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

Edward K. Avila; Marc Chamberlain; David Schiff; Jaap C. Reijneveld; Terri S. Armstrong; Roberta Ruda; Patrick Y. Wen; Michael Weller; Johan A.F. Koekkoek; Sandeep Mittal; Yoshiki Arakawa; Ali Choucair; Jorge Gonzalez-Martinez; David R. MacDonald; Ryo Nishikawa; Aashit Shah; Charles J. Vecht; Paula Warren; Martin J. Van Den Bent; Lisa M. DeAngelis

doi:https://doi.org/10.1093/neuonc/now190

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

Edward K. Avila, Marc Chamberlain, David Schiff, Jaap C. Reijneveld, Terri S. Armstrong, Roberta Ruda, Patrick Y. Wen, Michael Weller, Johan A.F. Koekkoek, Sandeep Mittal, Yoshiki Arakawa, Ali Choucair, Jorge Gonzalez-Martinez, David R. MacDonald, Ryo Nishikawa, Aashit Shah, Charles J. Vecht, Paula Warren, Martin J. Van Den Bent, Lisa M. DeAngelis

Research output: Contribution to journal › Review article › Academic › peer-review

95 Citations (Scopus)

Abstract

Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.

Original language	English
Pages (from-to)	12-21
Number of pages	10
Journal	Neuro-oncology
Volume	19
Issue number	1
DOIs	https://doi.org/10.1093/neuonc/now190
Publication status	Published - 2017

Keywords

Glioma
Low-grade
Metric
Scale
Seizures

Access to Document

https://doi.org/10.1093/neuonc/now190

Cite this

Avila, E. K., Chamberlain, M., Schiff, D., Reijneveld, J. C., Armstrong, T. S., Ruda, R., Wen, P. Y., Weller, M., Koekkoek, J. A. F., Mittal, S., Arakawa, Y., Choucair, A., Gonzalez-Martinez, J., MacDonald, D. R., Nishikawa, R., Shah, A., Vecht, C. J., Warren, P., Van Den Bent, M. J., & DeAngelis, L. M. (2017). Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-oncology, 19(1), 12-21. https://doi.org/10.1093/neuonc/now190

@article{ab493175614242e2b5d75da7a098a462,

title = "Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials",

abstract = "Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.",

keywords = "Glioma, Low-grade, Metric, Scale, Seizures",

author = "Avila, {Edward K.} and Marc Chamberlain and David Schiff and Reijneveld, {Jaap C.} and Armstrong, {Terri S.} and Roberta Ruda and Wen, {Patrick Y.} and Michael Weller and Koekkoek, {Johan A.F.} and Sandeep Mittal and Yoshiki Arakawa and Ali Choucair and Jorge Gonzalez-Martinez and MacDonald, {David R.} and Ryo Nishikawa and Aashit Shah and Vecht, {Charles J.} and Paula Warren and {Van Den Bent}, {Martin J.} and DeAngelis, {Lisa M.}",

year = "2017",

doi = "https://doi.org/10.1093/neuonc/now190",

language = "English",

volume = "19",

pages = "12--21",

journal = "Neuro-oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "1",

}

Avila, EK, Chamberlain, M, Schiff, D, Reijneveld, JC, Armstrong, TS, Ruda, R, Wen, PY, Weller, M, Koekkoek, JAF, Mittal, S, Arakawa, Y, Choucair, A, Gonzalez-Martinez, J, MacDonald, DR, Nishikawa, R, Shah, A, Vecht, CJ, Warren, P, Van Den Bent, MJ & DeAngelis, LM 2017, 'Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials', Neuro-oncology, vol. 19, no. 1, pp. 12-21. https://doi.org/10.1093/neuonc/now190

TY - JOUR

T1 - Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

AU - Avila, Edward K.

AU - Chamberlain, Marc

AU - Schiff, David

AU - Reijneveld, Jaap C.

AU - Armstrong, Terri S.

AU - Ruda, Roberta

AU - Wen, Patrick Y.

AU - Weller, Michael

AU - Koekkoek, Johan A.F.

AU - Mittal, Sandeep

AU - Arakawa, Yoshiki

AU - Choucair, Ali

AU - Gonzalez-Martinez, Jorge

AU - MacDonald, David R.

AU - Nishikawa, Ryo

AU - Shah, Aashit

AU - Vecht, Charles J.

AU - Warren, Paula

AU - Van Den Bent, Martin J.

AU - DeAngelis, Lisa M.

PY - 2017

Y1 - 2017

N2 - Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.

AB - Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.

KW - Glioma

KW - Low-grade

KW - Metric

KW - Scale

KW - Seizures

UR - http://www.scopus.com/inward/record.url?scp=85014025174&partnerID=8YFLogxK

U2 - https://doi.org/10.1093/neuonc/now190

DO - https://doi.org/10.1093/neuonc/now190

M3 - Review article

C2 - 27651472

SN - 1522-8517

VL - 19

SP - 12

EP - 21

JO - Neuro-oncology

JF - Neuro-oncology

IS - 1

ER -

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

Abstract

Keywords

Access to Document

Other files and links

Cite this